Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.

International immunopharmacology - 1 Sept 2023

Ma Zhou-Rui, Xiong Qian-Wei, Cai Shi-Zhong, Ding Ling-Tao, Yin Chao-Hong, Xia Hong-Liang, Liu Wei, Dai Shu, Zhang Yue, Zhu Zhen-Hong, Huang Zhi-Jian, Wang Qian, Yan Xiang-Ming

Abstract excerpt

This study aims to discern the possible molecular mechanism of the effect of ubiquitin-specific peptidase 18 (USP18) on the resistance to BRAF inhibitor vemurafenib in BRAF V600E mutant melanoma by regulating cyclic GMP-AMP synthase (cGAS). The cancer tissues of BRAF V600E mutant melanoma patients before and after vemurafenib treatment were collected, in which the protein expression of USP18 and cGAS was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mice, Nude

Share to Nucleotidyltransferases

Share to Sulfonamides

Share to Ubiquitin Thiolesterase

Share to Vemurafenib

Source

Identifiers

PMID: 37478666
DOI: 10.1016/j.intimp.2023.110617

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.PMID 37478666Read ↗

Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting TherapiesSemantic proximity Read ↗

USP18 Is Associated with PD-L1 Antitumor Immunity and Improved Prognosis in Colorectal CancerSemantic proximity Read ↗

MitoCur‐1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14Semantic proximity Read ↗

Deubiquitinating enzyme USP48 mediates pyroptosis and meliorates immune evasion in tumors by stabilizing GSDME expressionSemantic proximity Read ↗

Up‐regulated deubiquitinase USP 4 plays an oncogenic role in melanomaSemantic proximity Read ↗

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapiesSemantic proximity Read ↗

miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanomaSemantic proximity Read ↗

Hepatocyte growth factor promotes melanoma metastasis through ubiquitin-specific peptidase 22-mediated integrins upregulationSemantic proximity Read ↗

USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axisSemantic proximity Read ↗

RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1Semantic proximity Read ↗

Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti-PD-1 Therapy in NRAS-Mutant Melanoma.Semantic proximity Read ↗

USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.